Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | March 22, 2013

MR “Fingerprinting” Promises Quick Screen for Disease

Only one radiological modality – mammography – is used today for screening. Yet, as America hurdles toward preventive medicine, screening is where it will be at. Now researchers in Cleveland are floating the idea of using MRI as a standard procedure in annual checkups. 

This is not the MRI of the present, which sequesters patients inside a superconducting magnet for a half hour or more. This is a quick, radically new kind of MR – the MR equivalent of fingerprinting – that might one day scan whole patients for early signs of cancer, multiple sclerosis and heart disease in just a few minutes. And it can be done on a standard high-field scanner.

One of the investigators, Mark Griswold, Ph.D., a radiology professor at Case Western Reserve School of Medicine, says he and his colleagues “had to give up everything we knew about MRI and start over.”

Their work appeared March 13 in the online edition of the UK journal Nature, itself a nontraditional way of getting the word out on a radiological development. The president and CEO of Siemens Healthcare North America, which has been underwriting the research, believes this new technique could have broad ramifications for patients in five or ten years.

It’s taken a decade for the Cleveland team to get where they are now, doing much of the developmental work on a Siemens Espree 1.5T scanner. Scans done with the new technique reveal a fingerprint of tissue health, Griswold says, comprised of what might appear to be a cacophony of MR signals. These are produced by varying different parts of the electromagnetic fields that the Cleveland researchers use to probe the tissue. The signals carry information about key physical properties of the tissues. The signals are analyzed, quantified and charted to reveal patterns associated with health or specific diseases and their degree of progression.

In their Nature paper, the researchers report that MR fingerprinting “provides an alternative way to quantitatively detect and analyze complex changes that can represent physical alterations of a substance or early indicators of disease.”

If their preliminary results hold up, MR fingerprinting would be the first truly novel development coming out of MR in decades. And the timing couldn’t be better, given the push for healthcare reform and its emphasis on cost reduction, disease prevention and early treatment. 

Related Content

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...
Smart Breast Corporation (SmartBreast), a privately held company focused on breast cancer screening and detection, announced today that it has acquired certain molecular breast imaging (MBI) assets from Dilon Technologies, Inc. (Dilon) for an undisclosed amount.
News | Breast Imaging | January 04, 2021
January 4, 2021 — Smart Breast Corporation (SmartBreast), a privately held company focused on...